subscribeSubscribe
Acino completes acquisition of M8 Pharmaceuticals

Acino completes acquisition of M8 Pharmaceuticals
GLOBENEWSWIRE
04 Dec 2023
Share Share
UCB presents new data about the real-world experience of FINTEPLA

UCB presents new data about the real-world experience of FINTEPLA
PR NEWSWIRE
02 Dec 2023
Share Share
UCB Announces FINTEPLA® (fenfluramine) Oral Solution

UCB Announces FINTEPLA® (fenfluramine) Oral Solution
PR NEWSWIRE
17 Apr 2023
Share Share
CHMP recommends fenfluramine for LGS-associated seizures

CHMP recommends fenfluramine for LGS-associated seizures
EUROPEANPHARMACEUTICALREVIEW
20 Dec 2022
Share Share
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA
PRNEWSWIRE
23 Nov 2022
Share Share
NICE recommends UCB’s Fintepla for Dravet syndrome

NICE recommends UCB’s Fintepla for Dravet syndrome
Fleur Jeffries PHARMATIMES
01 Jun 2022
Share Share
Fenfluramine found effective in preventing drop seizures from LGS

Fenfluramine found effective in preventing drop seizures from LGS
Mandy Parrett EUROPEANPHARMACEUTICALREVIEW
04 May 2022
Share Share
JAMA Neurology Publishes PIII Study Results on Efficacy and Safety of FINTEPLA

JAMA Neurology Publishes PIII Study Results on Efficacy and Safety of FINTEPLA
PRNEWSWIRE
02 May 2022
Share Share
UCB takes on Jazz in severe epilepsy with new Fintepla label approval

UCB takes on Jazz in severe epilepsy with new Fintepla label approval
E. Sagonowsky PHARMAPHORUM
29 Mar 2022
Share Share
Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome

Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome
GLOBENEWSWIRE
04 Mar 2022
Share Share